Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma

Autor: Pablo Álvarez Ballesteros, Jesús Chamorro, Álvaro Ruiz Granados, María San Román-Gil, Javier Pozas, Javier Molina-Cerrillo, Victoria Gómez Dos Santos, Teresa Alonso-Gordoa, Enrique Grande
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Cancers
Cancers, Vol 13, Iss 5981, p 5981 (2021)
ISSN: 2072-6694
Popis: Simple Summary Renal cell carcinoma is particularly characterized by its high vascularization and dense immune cells infiltration. The angiogenesis blockade in combination with immune checkpoint inhibitors have supposed milestones in the treatment landscape of this tumor. This article gathers the available data on the mechanisms of resistance to current treatments, as well as new strategies under development to overcome these resistances. Abstract Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype arising from renal cell carcinomas. This tumor is characterized by a predominant angiogenic and immunogenic microenvironment that interplay with stromal, immune cells, and tumoral cells. Despite the obscure prognosis traditionally related to this entity, strategies including angiogenesis inhibition with tyrosine kinase inhibitors (TKIs), as well as the enhancement of the immune system with the inhibition of immune checkpoint proteins, such as PD-1/PDL-1 and CTLA-4, have revolutionized the treatment landscape. This approach has achieved a substantial improvement in life expectancy and quality of life from patients with advanced ccRCC. Unfortunately, not all patients benefit from this success as most patients will finally progress to these therapies and, even worse, approximately 5 to 30% of patients will primarily progress. In the last few years, preclinical and clinical research have been conducted to decode the biological basis underlying the resistance mechanisms regarding angiogenic and immune-based therapy. In this review, we summarize the insights of these molecular alterations to understand the resistance pathways related to the treatment with TKI and immune checkpoint inhibitors (ICIs). Moreover, we include additional information on novel approaches that are currently under research to overcome these resistance alterations in preclinical studies and early phase clinical trials.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje